Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy M Shefner

Showing results (91-100 of 105) with videos related to

Pageof 11
Sort By:
Muscle & Nerve|December 19, 2020
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trialMichael D Weiss, Eric A Macklin, Courtney E McIlduff, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 26, 2014
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristicsHiroshi Mitsumoto, Pam Factor-Litvak, Howard Andrews, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2022
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trialSabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, et al.
JAMA Neurology|November 23, 2020
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialBrian J Wainger, Eric A Macklin, Steve Vucic, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
The New England Journal of Medicine|September 3, 2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral SclerosisSabrina Paganoni, Eric A Macklin, Suzanne Hendrix, et al.
Pageof 11

Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Muscle & Nerve|December 19, 2020
Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trialMichael D Weiss, Eric A Macklin, Courtney E McIlduff, et al.
JAMA Neurology|March 24, 2025
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical TrialJeremy M Shefner, Merit E Cudkowicz, Angela Genge, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 12, 2025
Hospitalizations as an outcome measure in COURAGE-ALSStacy A Rudnicki, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|May 31, 2023
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of successJeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 26, 2014
ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristicsHiroshi Mitsumoto, Pam Factor-Litvak, Howard Andrews, et al.
The Lancet. Neurology|May 23, 2024
Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichael Benatar, Thomas Hansen, Dror Rom, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2022
Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trialSabrina Paganoni, Suzanne Hendrix, Samuel P Dickson, et al.
JAMA Neurology|November 23, 2020
Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical TrialBrian J Wainger, Eric A Macklin, Steve Vucic, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 24, 2020
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALSJeremy M Shefner, Jinsy A Andrews, Angela Genge, et al.
The New England Journal of Medicine|September 3, 2020
Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral SclerosisSabrina Paganoni, Eric A Macklin, Suzanne Hendrix, et al.
Pageof 11